Cochrane Abstracts
Chemotherapy for hormone‐refractory prostate cancer
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Chemotherapy for Hormone‐refractory Prostate Cancer." Cochrane Abstracts, John Wiley & Sons, Inc, 2024. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/432842/all/Chemotherapy_for_hormone‐refractory_prostate_cancer.
Chemotherapy for hormone‐refractory prostate cancer. Cochrane Abstracts. John Wiley & Sons, Inc; 2024. https://evidence.unboundmedicine.com/evidence/view/Cochrane/432842/all/Chemotherapy_for_hormone‐refractory_prostate_cancer. Accessed November 26, 2024.
Chemotherapy for hormone‐refractory prostate cancer. (2024). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/432842/all/Chemotherapy_for_hormone‐refractory_prostate_cancer
Chemotherapy for Hormone‐refractory Prostate Cancer [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2024. [cited 2024 November 26]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/432842/all/Chemotherapy_for_hormone‐refractory_prostate_cancer.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Chemotherapy for hormone‐refractory prostate cancer
ID - 432842
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/432842/all/Chemotherapy_for_hormone‐refractory_prostate_cancer
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
